Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study was a randomized, double-blind, multicenter phase III clinical study. A total of 226 patients with metastatic pancreatic ductal carcinoma who had failed or were intolerant to two previous standard therapies were planned.Subjects will be randomized in a 2:1 ratio to either the experimental group or the control group:Experimental Group: XNW28012 for Injection (2.4 mg/kg, administered once every 3 weeks);Control group: XNW28012 mimetic for Injection (administered once every 3 weeks).Both experimental and control subjects will receive optimal supportive care, including but not limited to nutritional support, adjustment of electrolyte balance, and cancer pain support treatment.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Zaawansowany rak trzustki (pancreatic ductal adenocarcinoma) potwierdzony badaniem histologicznym lub cytologicznym
- •Pogorszenie się choroby lub brak tolerancji po dwóch poprzednich standardowych chemioterapiach (gemcytabina i fluorouracyl)
- •Wiek 18 lat lub więcej w momencie wyrażenia zgody
- •Przynajmniej jeden mierzalny guz, który nie był wcześniej leczony lokalnie lub pokazuje wyraźny wzrost
- •Dobry stan ogólny pacjenta (ECOG 0-2)
- •Prawidłowe funkcje organów wewnętrznych (wątroba, nerki)
- •Dla kobiet w wieku rozrodczym: ujemny test ciążowy w ciągu 7 dni przed włączeniem do badania
- •Zgoda na stosowanie skutecznej antykoncepcji przez czas badania i 6 miesięcy po ostatniej dawce leku
✗ Disqualifies
- •Poważne reakcje alergiczne na terapie skojarzone przeciwciała-lek lub przeciwciała monoklonalne
- •Alergia na składniki leku XNW28012
- •Wcześniejsze leczenie podobnymi lekami z inhibitorami topoisomerazy I
- •Wcześniejsze leczenie innymi lekami ukierunkowanymi na ten sam cel terapeutyczny
Simplified criteria — AI translation
Trial details
- Last updated (source)
- September 16, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (48)
Fudan University Cancer Hospital
Shanghai, China
Beijing Friendship Hospital, Capital Medical University
Beijing, China
Beijing Tsinghua Changgung Hospital
Beijing, China
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Beijing, China
Affiliated Hospital of Binzhou Medical College
Binzhou, China
Hunan Cancer Hospital
Changsha, China
The First People's Hospital of Changzhou
Changzhou, China
Sichuan Provincial People's Hospital
Chengdu, China
West China Hospital, Sichuan University
Chengdu, China
Chongqing University Cancer Hospital
Chongqing, China
Fuyang Cancer Hospital
Fuyang, China
Fujian Cancer Hospital
Fuzhou, China
Union Hospital Affiliated to Fujian Medical University
Fuzhou, China
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, China
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
Hangzhou, China
Zhejiang Cancer Hospital
Hangzhou, China
Harbin Medical University Cancer Hospital
Ha’erbin, China
Anhui Provincial Cancer Hospital
Hefei, China
The First Hospital of Jilin University
Jilin City, China
Cancer Hospital Affiliated to Shandong First Medical University
Jinan, China
Jinan Central Hospital
Jinan, China
Gansu Provincial Cancer Hospital
Lanzhou, China
Meizhou People's Hospital
Meizhou, China
Jiangxi Provincial Cancer Hospital
Nanchang, China
The First Affiliated Hospital of Nanchang University
Nanchang, China
Jiangsu Cancer Hospital
Nanjing, China
Jiangsu Provincial People's Hospital
Nanjing, China
Nanjing Drum Tower Hospital Affiliated to Medical School of Nanjing University
Nanjing, China
Tumor Hospital Affiliated to Guangxi Medical University
Nanning, China
Peking University Cancer Hospital Inner Mongolia Hospital
Neimeng, China
People's Hospital Affiliated to Ningbo University
Ningbo, China
Shanghai East Hospital
Shanghai, China
Shanghai Fourth People's Hospital
Shanghai, China
Zhongshan Hospital, Fudan University
Shanghai, China
Liaoning Cancer Hospital
Shenyang, China
The First Affiliated Hospital of China Medical University
Shenyang, China
Shanxi Cancer Hospital
Taiyuan, China
The First Hospital of Shanxi Medical University
Taiyuan, China
Tianjin Cancer Hospital
Tianjin, China
Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China
The Second Affiliated Hospital of Xi 'an Jiaotong University
Xi'an, China
Xiamen Hospital of Traditional Chinese Medicine
Xiamen, China
Xiangyang Central Hospital
Xiangyang, China
Northern Jiangsu People's Hospital
Yangzhou, China
General Hospital of Ningxia Medical University
Yinchuan, China
Henan Cancer Hospital
Zhengzhou, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, China
Trial contact
Yingjie zhao
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/17/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.